Ptc Therapeutics (PTCT) Revenue (2012 - 2026)

Ptc Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $272.6 million for Q1 2026.

• On a quarterly basis, Revenue fell 76.83% year-over-year to $272.6 million in Q1 2026; TTM through Mar 2026 was $827.1 million, a 47.85% decrease from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 114.51% from the prior year.
• Revenue advanced to $272.6 million in Q1 2026 per PTCT's latest filing, from $164.7 million in the prior quarter.
• Across five years, Revenue topped out at $1.2 billion in Q1 2025 and bottomed at $148.7 million in Q1 2022.
• The 5-year median for Revenue is $210.6 million (2024), against an average of $266.2 million.
• Across the five-year window, Revenue surged 459.73% in 2025 and plunged 76.83% in 2026, its largest moves.
• Year by year, Revenue stood at $167.4 million in 2022, then soared by 83.41% to $307.1 million in 2023, then sank by 30.58% to $213.2 million in 2024, then decreased by 22.75% to $164.7 million in 2025, then jumped by 65.51% to $272.6 million in 2026.
• Per Business Quant, the three latest PTCT Revenue figures stand at $272.6 million (Q1 2026), $164.7 million (Q4 2025), and $211.0 million (Q3 2025).